8-K

UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

MYOMO, INC.

(Exact name of Registrant as Specified in Its Charter)

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Pursuant to the terms of that certain Securities Purchase Agreement dated Janaury 11, 2023 (the "Purchase Agreement") by and between Myomo, Inc. (the "Company") and investors identified on the signature pages thereto, including AIGH Capital Management LLC (collectively with its affiliates, "AIGH"), on January 26, 2023, the board of directors increased the size of the Board from five to six members and appointed Yitzchak Jacobovitz, selected and nominated by AIGH, as a Class II director effective January 27, 2023, to serve until the 2025 annual meeting of shareholders. Mr. Jacobovitz was not appointed to any committees of the Board. Any compensation arrangements for Mr. Jacobovitz are yet to be determined.

Mr. Jacobovitz, 47, is currently a partner and lead healthcare analyst at AIGH, where he has signifciantly grown AIGH's healthcare footprint since 2014. Prior to AIGH, Mr. Jacobovitz was a managing director at Capstone, a policy research firm and an analyst at Leap Tide Capital, a special situations hedge fund. Mr. Jacobovitz earned his Masters in Business Administration from Johns Hopkins University and is a Chartered Financial Analyst.

Except for the Purchase Agreement, there are no arrangements or understadings between Mr. Jacobovitz and any other person pursuant to which h was appointed as a director, and there are no prior, current or prposed transactions in which Mr. Jacobovitz had, has or will have a direct or indirect material interest and in which th Company was, is or will be a participant that requires disclosure pursuant to Item 404(a) of Regualtion S-K. For more information on the Purchase Agreement, see our Current Report on Form 8-K filed on Janaury 13, 2023, which is incorporated herein by reference.

On Janaury 30, 2023, the Company issued a press releas announcing the appointment of Mr. Jacobovitz. The full text of the press release annoucning the appointmnt of Mr. Jacobovitz to the Board is included as Exhibit 99.1 to this Current Report on Form 8-K.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

EX-99.1

Exhibit 99.1

Myomo Appoints Yitzchak Jacobovitz to its Board of Directors

BOSTON (January 30, 2023) - Myomo, Inc. (NYSE American: MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced the appointment of Yitzchak Jacobovitz as a Class II director effective January 27, 2023, to serve until the 2025 annual meeting of stockholders. With this appointment, Myomo has six directors.

Mr. Jacobovitz, 47, is a partner and lead healthcare analyst at AIGH Capital Management and affiliates (“AIGH”), where he has significantly grown AIGH’s healthcare footprint since joining in 2014. Prior to AIGH, Mr. Jacobovitz was a managing director at Capstone, a policy research firm and an analyst at Leap Tide Capital, a special situations hedge fund. Mr. Jacobovitz received his Masters in Business Administration from Johns Hopkins University and is a Chartered Financial Analyst

"We welcome Yitz to the Myomo Board of Directors and are gratified that AIGH was the lead investor in our most recent equity offering”, said Paul R. Gudonis, Chairman and Chief Executive Officer of Myomo. "Yitz brings extensive healthcare investment experience to our board, and we look forward to his contributions as we build value for our stockholders."

About Myomo

Myomo, Inc. is a wearable medical robotics company that offers improved arm and hand function for those suffering from neurological disorders and upper-limb paralysis. Myomo develops and markets the MyoPro product line. MyoPro is a powered upper-limb orthosis designed to support the arm and restore function to the weakened or paralyzed arms of certain patients suffering from CVA stroke, brachial plexus injury, traumatic brain or spinal cord injury, ALS or other neuromuscular disease or injury. It is currently the only marketed device that, sensing a patient’s own EMG signals through non-invasive sensors on the arm, can restore an individual’s ability to perform activities of daily living, including feeding themselves, carrying objects and doing household tasks. Many are able to return to work, live independently and reduce their cost of care. Myomo is headquartered in Boston, Massachusetts, with sales and clinical professionals across the U.S. and representatives internationally. For more information, please visit www.myomo.com.

Contacts:

For Myomo:

ir@myomo.com

Investor Relations:

Kim Sutton Golodetz

LHA Investor Relations

Myomo Inc. | 137 Portland Street 4th Floor | Boston, MA 02114

TEL: 877.736.9666 www.myomo.com info@myomo.com

DOCPROPERTY "DocID" \* MERGEFORMAT DM3\9352190.1

212-838-3777

kgolodetz@lhai.com

Myomo Inc. | 137 Portland Street 4th Floor | Boston, MA 02114

TEL: 877.736.9666 www.myomo.com info@myomo.com

DOCPROPERTY "DocID" \* MERGEFORMAT DM3\9352190.1